However, circulating levels of FGF21 are elevated in obesity and insulin-resistant states, therefore it is not clear if attempts to (in)directly increase levels further will be of therapeutic benefit in humans8, 11, 14. This evidence concerns the gene FGF21 and obesity due to melanocortin 4 receptor deficiency.